Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Koninklijke Philips N.V. or Boston Scientific Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Koninklijke Philips N.V. and Boston Scientific Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Koninklijke Philips N.V. and Boston Scientific Corporation

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Latest Health Care Equipment & Supplies and Koninklijke Philips N.V., Boston Scientific Corporation Stock News

As of July 31, 2026, Koninklijke Philips N.V. had a $25.6 billion market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. Koninklijke Philips N.V.’s stock is down 2.9% in 2026, up 0.5% in the previous five trading days and down 1.9% in the past year.

Currently, Koninklijke Philips N.V.’s price-earnings ratio is 20.2. Koninklijke Philips N.V.’s trailing 12-month revenue is $20.2 billion with a 6.3% net profit margin. Year-over-year quarterly sales growth most recently was -2.2%. Analysts expect adjusted earnings to reach $1.763 per share for the current fiscal year. Koninklijke Philips N.V. does not currently pay a dividend.

As of July 31, 2026, Boston Scientific Corporation had a $69.5 billion market cap, putting it in the 95th percentile of all stocks. Boston Scientific Corporation’s stock is down 51% in 2026, up 5.6% in the previous five trading days and down 56.23% in the past year.

Currently, Boston Scientific Corporation’s price-earnings ratio is 19.6. Boston Scientific Corporation’s trailing 12-month revenue is $20.6 billion with a 17.5% net profit margin. Year-over-year quarterly sales growth most recently was 11.6%. Analysts expect adjusted earnings to reach $3.304 per share for the current fiscal year. Boston Scientific Corporation does not currently pay a dividend.

How We Compare Koninklijke Philips N.V. and Boston Scientific Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Koninklijke Philips N.V. and Boston Scientific Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Koninklijke Philips N.V. and Boston Scientific Corporation Stock Value Grades

Company	Ticker	Value
Koninklijke Philips N.V.	PHG	C
Boston Scientific Corporation	BSX	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Koninklijke Philips N.V. has a Value Score of 60, which is Average. Boston Scientific Corporation has a Value Score of 30, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Koninklijke Philips N.V. or Boston Scientific Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Koninklijke Philips N.V. or Boston Scientific Corporation is the better investment when it comes to value.

Koninklijke Philips N.V. and Boston Scientific Corporation’s Quality Grades

Company	Ticker	Quality
Koninklijke Philips N.V.	PHG	A
Boston Scientific Corporation	BSX	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Koninklijke Philips N.V. has a Quality Score of 95, which is Very Strong. Boston Scientific Corporation has a Quality Score of 86, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Koninklijke Philips N.V. and Boston Scientific Corporation have a grade of A. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Koninklijke Philips N.V. and Boston Scientific Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Koninklijke Philips N.V.	PHG	D
Boston Scientific Corporation	BSX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Koninklijke Philips N.V. has a Earnings Estimate Score of 22, which is Negative. Boston Scientific Corporation has a Earnings Estimate Score of 42, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Koninklijke Philips N.V. or Boston Scientific Corporation has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Koninklijke Philips N.V. or Boston Scientific Corporation is the better investment when it comes to estimate revisions.

Other Koninklijke Philips N.V. and Boston Scientific Corporation Grades

In addition to Estimate Revisions, Value and Quality, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Koninklijke Philips N.V. and Boston Scientific Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Koninklijke Philips N.V. or Boston Scientific Corporation Stock?

Overall, Koninklijke Philips N.V. stock has a Value Score of 60, Estimate Revisions Score of 22 and Quality Score of 95.

Boston Scientific Corporation stock has a Value Score of 30, Estimate Revisions Score of 42 and Quality Score of 86.

Comparing Koninklijke Philips N.V. and Boston Scientific Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.